ARVINAS, INC.(ARVN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,264 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ARVN
Events flagged as statistical outliers against ARVN's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-09-06
ARVN quality score dropped 24 points (36→13) on a new filing
View source filing →
ARVN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ARVINAS, INC. (ARVN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARVN at 36.6/100 on a 32-signal composite quality model, placing it at rank #2,264 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.3) and free cash flow (8.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ARVINAS, INC. reports quarterly revenue of $249.7M, net income of $169.4M, free cash flow of $-48.5M. Top institutional holders of ARVN by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, D. E. Shaw, based on the most recent SEC filings. ARVN trades on the Nasdaq exchange and files with the SEC under CIK 1655759. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARVINAS, INC. directly from SEC EDGAR. ARVINAS, INC.'s 13F Pro composite quality score has ranged between 8 and 46 since 2021, currently 36.6 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.
Revenue
Q2 2026
$249.7M
Net Income
Q2 2026
$169.4M
Free Cash Flow
Q2 2026
$-48.5M
D/E Ratio
Q2 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-0.3% YoYNet Income
+59.4% YoYOperating Income
+52.6% YoYEPS (Diluted)
+58.8% YoYTotal Assets
-34.2% YoYTotal Debt
-20.0% YoYOp. Cash Flow
-5.6% YoYFree Cash Flow
-5.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $262.6M -0.3% | $263.4M +235.5% | $78.5M -40.3% | $131.4M +145.1% | $53.6M +106.9% | $25.9M |
| Net Income | $-80.8M +59.4% | $-198.9M +45.8% | $-367.3M -30.0% | $-282.5M -47.9% | $-191.0M -60.1% | $-119.3M |
| Operating Income | $-118.5M +52.6% | $-250.2M +37.7% | $-401.5M -52.5% | $-263.2M -39.7% | $-188.4M -56.0% | $-120.8M |
| EPS (Diluted) | $-1.14 +58.8% | $-2.77 +58.2% | $-6.62 -24.7% | $-5.31 -39.0% | $-3.82 -26.5% | $-3.02 |
| Total Assets | $717.9M -34.2% | $1.09B -16.3% | $1.30B +2.8% | $1.27B -19.8% | $1.58B +120.5% | $717.4M |
| Total Debt | $800.0K -20.0% | $1.0M -16.7% | $1.2M +20.0% | $1.0M +0.0% | $1.0M -50.0% | $2.0M |
| Operating Cash Flow | $-273.8M -5.6% | $-259.3M +25.4% | $-347.8M -27.2% | $-273.5M -148.9% | $559.4M +723.6% | $-89.7M |
| Free Cash Flow | $-275.7M -5.6% | $-261.1M +25.5% | $-350.7M -25.1% | $-280.3M -150.5% | $554.7M +677.2% | $-96.1M |
Get alerted when ARVN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ARVINAS, INC. including:
Top Institutional Holders of ARVN
BlackRock, Inc.
$63.2M7,609,123 shVANGUARD PORTFOLIO MANAGEMENT LLC
$34.3M4,123,399 shD. E. Shaw & Co., Inc.
$29.0M3,495,153 shPFIZER INC
$27.7M3,457,815 shARMISTICE CAPITAL, LLC
$23.2M2,796,000 shVANGUARD CAPITAL MANAGEMENT LLC
$22.6M2,714,163 shTWO SIGMA INVESTMENTS, LP
$21.4M2,573,447 shSTATE STREET CORP
$18.3M2,196,872 shNextech Invest, Ltd.
$17.1M1,122,713 shGEODE CAPITAL MANAGEMENT, LLC
$13.9M1,667,265 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $63.2M | 7,609,123 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $34.3M | 4,123,399 |
| D. E. Shaw & Co., Inc. | $29.0M | 3,495,153 |
| PFIZER INC | $27.7M | 3,457,815 |
| ARMISTICE CAPITAL, LLC | $23.2M | 2,796,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.6M | 2,714,163 |
| TWO SIGMA INVESTMENTS, LP | $21.4M | 2,573,447 |
| STATE STREET CORP | $18.3M | 2,196,872 |
| Nextech Invest, Ltd. | $17.1M | 1,122,713 |
| GEODE CAPITAL MANAGEMENT, LLC | $13.9M | 1,667,265 |
Companies Similar to ARVN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Janux Therapeutics, Inc.
MACROGENICS INC
Evolus, Inc.
Schrodinger, Inc.
Xeris Biopharma Holdings, Inc.
Immunocore Holdings plc
SI-BONE, Inc.
Journey Medical Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ARVN on your watchlist
Track score changes the day ARVINAS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ARVN a good stock to buy?
13F Pro's AI-powered analysis of ARVINAS, INC. (ARVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARVN are available on the ARVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ARVN is classified as a small company.
Which hedge funds own ARVN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARVINAS, INC.'s investment landscape.